Its phase 2 results for samelisant which is used to treat narcolepsy, associated with sleep cycle. The medicine has less side effects compared to pitolisant and oxybates, which are currently the preferred method for treating narcolepsy. The question on efficacy remains, which will be disclosed post phase 2 trials. The most interesting part is, in narcolepsy, there is an opportunity for out licensing post phase 2 trials, as was seen in the case of sumitomo pharma’s drug for narcolepsy. In such arrangements, the company licensing it pays an amount upfront, for conclusion of phase 3 trials plus there is also a royalty associated. Opportunity size is huge, as narcolepsy drugs is a billion dollar market, and suven lifesciences market cap is just 1000cr. However, everything depends on phase 2 trial results, which is expected anytime between September- October.
Disclosure: Invested and biased.
| Subscribe To Our Free Newsletter |
